CLINICAL OUTCOMES OF INTRAVESICAL CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Non-muscle invasive bladder cancer (NMIBC) is characterized by a high recurrence rate and risk of progression. In settings where Bacillus Calmette–Guérin (BCG) immunotherapy is not available, intravesical chemotherapy remains the cornerstone of adjuvant treatment. However, data comparing different chemotherapeutic agents in routine practice remain limited.
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2025-09-30
- DOI
- https://doi.org/10.5281/zenodo.17233237
- Primary Topic
- Geochemistry and Geologic Mapping
- Type
- article
- Field-Weighted Citation Impact
- 0.00